BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 27074700)

  • 1. Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
    Rosen T; Stein Gold LF
    Semin Cutan Med Surg; 2016 Mar; 35(3 Suppl 3):S51-5. PubMed ID: 27074700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis.
    Gupta G; Foley KA; Gupta AK
    Skin Therapy Lett; 2015 Nov; 20(6):6-9. PubMed ID: 27224843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efinaconazole and Tavaborole.
    Poulakos M; Grace Y; Machin JD; Dorval E
    J Pharm Pract; 2017 Apr; 30(2):245-255. PubMed ID: 26873506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.
    Gupta AK; Daigle D
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):735-42. PubMed ID: 24894552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on tavaborole for the treatment of onychomycosis.
    Jinna S; Finch J
    Drug Des Devel Ther; 2015; 9():6185-90. PubMed ID: 26640371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of tavaborole for the treatment of onychomycosis.
    Gupta AK; Daigle D
    Future Microbiol; 2014; 9(11):1243-50. PubMed ID: 25437186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onychomycosis.
    Welsh O; Vera-Cabrera L; Welsh E
    Clin Dermatol; 2010 Mar; 28(2):151-9. PubMed ID: 20347657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice.
    Rich P; Vlahovic TC; Joseph WS; Zane LT; Hall SB; Gellings Lowe N; Adigun CG
    Cutis; 2017 Oct; 100(4):259-264. PubMed ID: 29136060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onychomycosis: Treatment and prevention of recurrence.
    Lipner SR; Scher RK
    J Am Acad Dermatol; 2019 Apr; 80(4):853-867. PubMed ID: 29959962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tavaborole - a treatment for onychomycosis of the toenails.
    Gupta AK; Versteeg SG
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1145-52. PubMed ID: 27347905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction.
    Stein Gold LF; Rosen T
    Semin Cutan Med Surg; 2016 Mar; 35(3 Suppl 3):S47. PubMed ID: 27096143
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapies for the treatment of onychomycosis.
    Gupta AK; Paquet M; Simpson FC
    Clin Dermatol; 2013; 31(5):544-54. PubMed ID: 24079583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral treatment options for onychomycosis.
    Joseph WS
    J Am Podiatr Med Assoc; 1997 Nov; 87(11):520-31. PubMed ID: 9397657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
    Gupta AK; Gregurek-Novak T
    Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal agents for onychomycosis: new treatment strategies to improve safety.
    Zane LT; Chanda S; Coronado D; Del Rosso J
    Dermatol Online J; 2016 Mar; 22(3):. PubMed ID: 27136621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
    Gupta AK
    J Am Podiatr Med Assoc; 2002 May; 92(5):272-86. PubMed ID: 12015408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA.
    Gupta AK; Lambert J
    Int J Dermatol; 1999 Sep; 38 Suppl 2():53-64. PubMed ID: 10515529
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessing treatment outcomes in toenail onychomycosis clinical trials.
    Werschler WP; Bondar G; Armstrong D
    Am J Clin Dermatol; 2004; 5(3):145-52. PubMed ID: 15186193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
    Van Doorslaer EK; Tormans G; Gupta AK; Van Rossem K; Eggleston A; Dubois DJ; De Doncker P; Haneke E
    Dermatology; 1996; 193(3):239-44. PubMed ID: 8944348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.